Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Immunotherapy
100%
Malignant Neoplasm
100%
Immune Checkpoint Inhibitor
100%
Steroids
20%
Complication
10%
Toxicity
10%
Diarrhea
10%
Metastatic Melanoma
10%
Rash
10%
Immunosuppressive Agent
10%
Advanced Cancer
10%
Pruritus
10%
Drug
10%
Lung Cancer
10%
Colitis
10%
Ipilimumab
10%
Pembrolizumab
10%
Nivolumab
10%
Survival
10%
Medicine and Dentistry
Adverse Event
100%
Cancer Immunotherapy
100%
Steroid
20%
Therapeutic Procedure
20%
Gastrointestinal Tract
20%
Organ
20%
Complication
10%
Awareness
10%
Diagnosis
10%
Diarrhea
10%
Toxicity
10%
Lung Cancer
10%
Malignant Neoplasm
10%
Metastatic Melanoma
10%
Chemotherapeutic Agent
10%
Immunotherapy
10%
Combination Therapy
10%
Colitis
10%
Immunosuppressive Drug
10%
Exanthem
10%
Advanced Cancer
10%
Pruritus
10%
Drug
10%
Life
10%
Ipilimumab
10%
Nivolumab
10%
Pembrolizumab
10%
Attention
10%
Endocrine System
10%
Survival
10%
Physician
10%
Clinician
10%
Medication
10%
Thyroid Gland
10%
Nursing and Health Professions
Adverse Event
100%
Cancer Immunotherapy
100%
Patient
60%
Combination Therapy
20%
Steroid
20%
Electric Potential
20%
Physician
10%
Complication
10%
Clinician
10%
Diagnosis
10%
Drug Therapy
10%
Lung Cancer
10%
Pruritus
10%
Toxicity
10%
Immunotherapy
10%
Immunosuppressive Agent
10%
Diarrhea
10%
Metastatic Melanoma
10%
Survival
10%
Malignant Neoplasm
10%
Drug
10%
Rash
10%
Ipilimumab
10%
Nivolumab
10%
Colitis
10%
Advanced Cancer
10%
Biochemistry, Genetics and Molecular Biology
Cancer Immunotherapy
100%
Steroid
20%
Electric Potential
20%
Awareness
10%
Life
10%
Survival
10%
Attention
10%
Ipilimumab
10%
Pembrolizumab
10%
Neuroscience
Cancer Immunotherapy
100%
Steroids
20%
Immunotherapy
10%
Thyroid
10%
Endocrine System
10%
Ipilimumab
10%
Lambrolizumab
10%
Nivolumab
10%